A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.

Phase 1 Completed 14 enrolled Pfizer

NaSingle-groupOpen-labelOther

Summary

The purpose of this Phase 1 clinical trial is to help us understand how the drug is changed and eliminated from your body after you take it, the safety, and the the extent to which dise effects can be tolerated of PF-07321332 when PF-07321332 and ritonavir are given to healthy adult Chinese participants.

Timeline

Start: 2022-03-10
Primary completion: 2022-04-21
Completion: 2022-04-21

Publications

Li N, Yu J, Wu J, Zhang J, Ma Y, Zhang C, Han X, Gerhart J, Cong S. Pharmacokinetics of Nirmatrelvir/Ritonavir after Multiple Administration in a Phase 1, Open-Label Study in Healthy Chinese Adults and Compared with Non-Chinese Participants. Clin Drug Investig. 2026 Jul;46(7):783-793. doi: 10.1007/s40261-026-01554-y. Epub 2026 May 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nirmatrelvir	Small molecule	300 mg	Oral
Subject	Ritonavir	Other / unclassified	100 mg	Oral

Indications

No indication recorded.